Phase II Study of Gemcitabine plus Cisplatin in Patients with Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer
Open Access
- 1 January 2008
- journal article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 40 (3), 101-105
- https://doi.org/10.4143/crt.2008.40.3.101
Abstract
Metastatic breast cancer patients are usually exposed to taxane and anthracycline as neoadjuvant, adjuvant and palliative chemotherapeutic agents. This study was designed to determine the efficacy and safety of the use of a gemcitabine and cisplatin (GP) combination treatment in patients with metastatic breast cancer that were pretreated with anthracycline and taxane. We evaluated the use of a GP regimen (1,000 mg/m(2) gemcitabine administered on days 1 and 8 plus 60 mg/m(2) cisplatin administered on day 1 every 3 weeks) in 38 breast cancer patients who had received prior chemotherapy with anthracycline and taxane as an adjuvant or neoadjuvant therapy, or as a palliative therapy. The median patient age was 49 years (age range, 35 approximately 69 years). The overall response rate was 28.9% in 11 patients (95% confidence interval [CI], 14 approximately 44%). The median time to progression was 5.2 months (95% CI, 3.6 approximately 6.8 months). Median survival was 19.5 months (95% CI, 11.2 approximately 27.8 months). Major grade 3/4 hematological toxicity was due to leukopenia (36 of 157 cycles, 23.1%). Non-hematological toxicity was rarely severe; grade 1/2 nausea and vomiting were observed in 37.8% of the patients. There were no treatment related deaths. Our results suggest that the use of gemcitabine plus cisplatin appears to be effective and has an acceptable toxicity profile in patients with advanced breast cancer that have been pretreated with anthracycline and taxane.Keywords
This publication has 25 references indexed in Scilit:
- Overview of Gemcitabine Activity in Advanced Breast CancerSeminars in Oncology, 2006
- Role of Gemcitabine in Breast Cancer Management: An UpdateSeminars in Oncology, 2006
- High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancerCancer Chemotherapy and Pharmacology, 2005
- Gemcitabine plus Paclitaxel as First-Line Chemotherapy for Patients with Advanced Breast CancerOncology, 2004
- 2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 HospitalsCancer Research and Treatment, 2004
- Monotherapy options in the management of metastatic breast cancerSeminars in Oncology, 2003
- Platinum Compounds in the Treatment of Advanced Breast CancerClinical Breast Cancer, 2001
- Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancerThe Breast, 2000
- Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancerAnti-Cancer Drugs, 1999
- Treatment of Breast CancerNew England Journal of Medicine, 1998